Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer

被引：0
|
作者：
Liu, Zaoqu [1 ]
Shan, Dan [2 ]
Han, Xinwei [3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Beijing, Peoples R China
[2] Univ Hosp Galway, Clin Sci Inst, Galway, Ireland
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, Zhengzhou, Peoples R China
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2025年 / 333卷 / 02期
关键词：
D O I：
10.1001/jama.2024.23091
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer
    Wang, J.
    Chen, K.
    Bai, H.
    Zhao, J.
    Wang, Z.
    Zhuo, M.
    An, T.
    Duan, J.
    Yang, L.
    Wu, M.
    Guo, Q.
    Liu, X.
    Wang, S.
    Wang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Clinical outcomes of EGFR plus /METamp plus vs. EGFR plus /METamp- untreated patients with advanced non-small cell lung cancer
    Peng, Kai-Cheng
    Su, Jun-Wei
    Xie, Zhi
    Wang, Han-Min
    Fang, Mei-Mei
    Li, Wen-Feng
    Chen, Yu-Qing
    Guan, Xu-Hui
    Su, Jian
    Yan, Hong-Hong
    Zhang, Xu-Chao
    Tu, Hai-Yan
    Zhou, Qing
    Chen, Hua-Jun
    Wu, Yi-Long
    Yang, Jin-Ji
    THORACIC CANCER, 2022, 13 (11) : 1619 - 1630
  • [43] Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Yulong
    Yan, Bo
    Zhang, Ran
    Zhao, Gang
    You, Jian
    HELIYON, 2023, 9 (09)
  • [44] Neoadjuvant atezolizumab plus chemotherapy in resectable non-small cell lung cancer (NSCLC).
    Shu, Catherine A.
    Grigg, Claud
    Chiuzan, Codruta
    Garofano, Robert F.
    Patel, Vijeta
    Hernandez, Susana
    Negri, Tiffany
    Sacher, Adrian G.
    Smith-Marrone, Stephanie
    Stoopler, Mark
    Gainor, Justin F.
    Awad, Mark M.
    D'Ovidio, Frank
    Sonett, Joshua R.
    Bacchetta, Matthew
    Saqi, Anjali
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Y.
    Yan, B.
    You, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S108 - S109
  • [46] Non-small cell lung cancer second line chemotherapy with gemcitabin plus vinorelvine
    Camps, C
    Nogueron, E
    Berrocal, A
    Albert, A
    Godes, MJ
    Muñoz, J
    Vicent, JM
    Safont, MJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
  • [47] Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases
    Qin, H.
    Wang, S.
    Gao, F.
    Zeng, Z.
    Liu, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S967 - S967
  • [48] Effectiveness of osimertinib plus chemotherapy and avastin for untreated EGFR-mutated advanced non-small cell lung cancer.
    Wang, Fang
    Liu, Hui
    Zeng, Zhen
    Wang, Shasha
    Qin, Haifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
    Jian, Hong
    Li, Wei
    Ma, Zhiyong
    Huang, Jianjin
    Feng, Jifeng
    Song, Yong
    Gao, Beili
    Zhu, Huili
    Tao, Min
    Bai, Chong
    Ma, Shenglin
    Pan, Hongming
    Qin, Shukui
    Hua, Dong
    Yu, Yongfeng
    Lu, Shun
    SCIENTIFIC REPORTS, 2017, 7
  • [50] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
12345